Epidemiology and gene markers of ulcerative colitis in the Chinese

Yun, Jun Won; Xu, Cheng; Pan, Bo‐Rong

doi:10.3748/wjg.15.788

Cited by 33 publications

(31 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In China, the number of patients with ulcerative colitis (UC) in China has increased threefold in the past 10 years [14,15]. Therefore, the number of patients with colorectal cancer (CRC) associated with UC might also increase since there is an increased risk of CRC in UC.…”

Section: Introductionmentioning

confidence: 99%

Risk of Ulcerative Colitis-Associated Colorectal Cancer in China: A Multi-Center Retrospective Study

Gong

Wang

et al. 2011

Dig Dis Sci

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Risk of Ulcerative Colitis-Associated Colorectal Cancer in China: A Multi-Center Retrospective Study

Gong

Wang

et al. 2011

Dig Dis Sci

View full text Add to dashboard Cite

show abstract

“…This is the first study that demonstrated a link between NOD2 genotype and UC phenotype. Regional heterogeneity within the NOD2 genotype in UC patients shows the importance of the genetic assessment and evaluation of its correlation with the phenotype in different populations [4,5,10,[12][13][14][15]50]. In addition, other potential genetic predictors and detailed information about environmental exposure should be assessed in future studies, because the lowpenetrance genetic effects of common SNPs may largely depend on interaction with other determinant factors.…”

Section: Discussionmentioning

confidence: 99%

“…Three major NOD2 SNPs, two missense [R702W, G908R] and one frameshift (1,007 fs), were shown by independent groups to be associated with susceptibility to CD [6,7,[9][10][11]. By contrast, even though most available data showed no link between NOD2 mutations and susceptibility to UC, a few recent studies have reached different conclusions, and so this matter remains somewhat controversial [4,5,10,[12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%

NOD2 gene mutations in ulcerative colitis: useless or misunderstood?

Freire

Cardoso

Figueiredo

et al. 2014

Int J Colorectal Dis

View full text Add to dashboard Cite

Purpose NOD2 mutations have been linked to an increased risk of Crohn's disease and to some of its phenotypes. The association between NOD2 mutations and susceptibility to ulcerative colitis (UC) remains somewhat controversial and potential correlations between these mutations and UC phenotype have not been studied. Aim To assess whether NOD2 mutations are a risk factor for UC in Portugal and if there are any genotype-phenotype correlations in these patients. Methods The three main NOD2 mutations were searched in 200 patients with UC and in 202 healthy controls. Results NOD2 mutations were present in 28 patients with UC (14.0 %) and in 27 controls (13.4 %) (p=0.853). Mutation carriers were more likely to receive steroids during the first year of disease than non-carriers (54.2 % vs. 29.6 %, p= 0.018) and among these patients the need for intravenous administration was more frequent in those with the R702W polymorphism (90.0 % vs. 45.5 %, p=0.014). In patients with severe colitis admitted for intravenous steroids, a greater proportion of mutation carriers was considered intravenous-steroid refractory and required salvage therapy (90.0 % vs. 38.1 %, p=0.004). Patients with NOD2 mutation were submitted to colectomy more frequently than non-carriers (17.9 % vs. 4.1 %. p=0.015). No correlation with the need for immunosuppressants/immunomodulators was found. Conclusions In the Portuguese population, NOD2 mutations do not increase the risk of UC but are associated with a more aggressive course including greater need of steroids in the first

show abstract

“…Epidemiologic data support genetic contribution to the pathogenesis of IBD. Recently, numerous new genes have been identified to be involved in the genetic susceptibility to IBD [5]: TNF-308A, CARD15 (NOD2), MIF-173 gene, N-acetyltransferase 2 (NAT2), NKG2D (natural killer cell 2D), STAT6 (signal transducer and activator of transcription 6), CTLA-4 (cytotoxic T lymphocyte antigen-4), MICA-MICB (major histocompatibility complex A and B), HLA-DRB1 gene, HLA class-II gene, IL-18 gene (interleukin-18 gene), IL-4 gene, MICA-A5, CD14 gene, TLR4 gene, Fas-670 gene, p53 gene and NF-kappaB. The characterization of these novel genes is potential to identify therapeutic agents and clinical assessment of phenotype and prognosis in patients with IBD (UC and CD).…”

mentioning

confidence: 99%